Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

1. Biogen proposed to acquire all outstanding Sage shares at $7.22 each. 2. Sage shares rose 5.13% following Biogen's acquisition proposal. 3. Biogen's move may impact their strategic positioning in the market. 4. The acquisition could influence Biogen's financial health and stock performance. 5. Market reaction indicates investor interest in Biogen's potential growth.